The development of new combination therapy with deferasirox and sorafenib on advanced hepatocellular carcinama
Project/Area Number |
23590978
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Gastroenterology
|
Research Institution | Yamaguchi University |
Principal Investigator |
YAMASAKI Takahiro 山口大学, 医学(系)研究科(研究院), 教授 (00304478)
|
Co-Investigator(Kenkyū-buntansha) |
YAMAMOTO Naoki 山口大学, 大学教育機構, 講師 (90448283)
TERAI Shuji 山口大学, 大学院医学系研究科, 准教授 (00332809)
SAKAIDA Isao 山口大学, 大学院医学系研究科, 教授 (80263763)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 鉄キレート剤 / CDAAモデル / Deferasirox / Sorafenib / Deferoxamine / DEN肝発癌モデル / 肝細胞癌 / DEN発癌モデル / Deferoximine |
Research Abstract |
Sorafenib is expected to have a chemopreventive effect on hepatocellular carcinoma (HCC). However, there are limitations to its use because of adverse effects, including effects on liver function. We have reported that the iron chelator deferoxamine can prevent liver fibrosis and preneoplastic lesions. We investigated the influence of administering an oral iron chelator, deferasirox (DFX), on the effects of sorafenib. The combination of DFX+sorafenib markedly prevented liver fibrosis and preneoplastic lesions better than the other treatments. Furthermore, the combination therapy produced significantly fewer adverse effects such as body weight and hand-foot skin syndrome compared with the sorafenib group. The combination therapy with DFX and sorafenib may be a useful adjuvant therapy to prevent recurrence after curative treatment of HCC.
|
Report
(4 results)
Research Products
(71 results)
-
[Journal Article] Systemic gemcitabine combined with hepatic arterial infusion chemotherapy with cisplatin, 5-fluorouracil, and isovorin for the treatment of advanced intrahepatic cholangiocarcinoma: A pilot study2014
Author(s)
Marumoto M, Yamasaki T, Marumoto Y, Saeki I, Harima Y, Urata Y, Hidaka I, Ishikawa T, Takami T, Segawa M, Yamaguchi Y, Uchida K, Terai S, Sakaida I.
-
Journal Title
Hepatogastroenterology
Volume: 印刷中
Related Report
-
-
-
-
[Journal Article] Association of tyrosine with insulin resistance in hepatitis C virus-related chronic liver disease.2013
Author(s)
Oono T, Yamasaki T, Zaitsu J, Saeki I, Iwamoto T, Harima Y, Marumoto Y, Hidaka I, Urata Y, Ishikawa T, Takami T, Segawa M, Uchida K, Terai S, Kunitugu I, Tanabe T, Sakaida I
-
Journal Title
Hepatol Res.
Volume: Aug 1
Issue: 10
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy : current status in Japan2013
Author(s)
Sato A, Sata M, Ikeda K, Kumada T, Izumi N, Asahina Y, Osaki Y, Chayama K, Kaneko S, Sakai A, Onji M, Hiasa Y, Omura T, Ozeki I, Yokosuka O, Shiina S, Itsubo M, Nishiguchi S, Hirano K, Ide T, Sakisaka S, Yamasaki T, Hidaka I, Tanaka M, Kim SR, Ichida T
-
Journal Title
Intern Med
Volume: 52(24)
Pages: 2701-6
NAID
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Association of tyrosine with insulin resistance in hepatitis C virus-related chronic liver disease2013
Author(s)
Takahiro Yamasaki, Takashi Oono, Junichi Zaitsu, Issei Saeki, Yoshio Marumoto, Isao Hidaka, Yohei Urata, Tsuyoshi Ishikawa, Taro Takami, Koichi Uchida, Shuji Terai, Isao Sakaida
Organizer
64th Annual Liver Meeting in AASLD 2013
Place of Presentation
Washington Convention Center(Washington DC USA)
Related Report
-
[Presentation] The new oral iron chelator, Deferasirox, is the new drug to prevent Liver Fibrosis and Hepatocarcinogenesis2013
Author(s)
Naoki Yamamoto, Takahiro Yamasaki, Koichi Uchida, Norikazu Tanabe, Taro Takami, Issei Saeki, Koichi Fujisawa, Masaki Maeda, Shuji Terai, Isao Sakaida
Organizer
64th Annual Liver Meeting in AASLD 2013
Place of Presentation
Washington Convention Center(Washington DC USA)
Related Report
-
-
-
-
[Presentation] Serum transferrin as a predictor of prognosis for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma2013
Author(s)
Takahiro Yamasaki, Issei Saeki, Junichi Zaitsu, Yohei Harima, Takuya Iwamoto, Yumiko Harima, Toshihiko Matsumoto, Yohei Urata, Isao Hidaka, Yoshio Marumoto, Tsuyoshi Ishikawa, Taro Takami, Naoki Yamamoto, Seiji Kaino, Koichi Uchida, Shuji Terai, Isao Sakaida
Organizer
The 23rd Conference of the Asian Pacific Association for the Study of the Liver(APASL) 2013
Place of Presentation
Suntec Singapole(Singapole)
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-